A critical assessment of composite and coprimary endpoints: A complex problem
- 30 November 2008
- journal article
- editorial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 59 (5), 890-896
- https://doi.org/10.1016/j.jaad.2008.05.021
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Clobetasol propionate emulsion formulation foam 0.05%: Review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescentsJournal of the American Academy of Dermatology, 2008
- Challenge of multiple co‐primary endpoints: a new approachStatistics in Medicine, 2006
- Some issues with composite endpoints in clinical trialsFundamental & Clinical Pharmacology, 2005
- Key Issues in End Point Selection for Heart Failure Trials: Composite End PointsJournal of Cardiac Failure, 2005
- Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy OutcomesNew England Journal of Medicine, 2005
- Validity of composite end points in clinical trialsBMJ, 2005
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisJournal of the American Academy of Dermatology, 2004
- Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issuesStatistics in Medicine, 2003
- Multiple Testings: Multiple Comparisons and Multiple EndpointsDrug Information Journal, 1998
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978